Microdose Launches Special Report Spotlighting Intellectual Property & Patents in Psychedelic Drug Development

This IP & Patents Report is the inaugural business and data intelligence report from Microdose, as well as the precursor to the upcoming Psychedelic Industry Report. Sponsorship opportunities are available for the full Psychedelic Industry Report; please contact Christina Cassen to discuss: [email protected].

The modern psychedelic renaissance has empirically proven that psychedelic drugs are going to revolutionize mental health treatment. Before these incredibly promising medicines can get to the people who need them the most, they must pass through the extensive drug development pipeline, where IP & Patents are crucial. Since the drug development pathway is considerably expensive, difficult and time-consuming, Microdose is pleased to announce the release of our IP & Patents Report, which features vital information regarding intellectual property and the patentability of novel psychedelic drugs, delivery mechanisms, and more, compiled by leading experts in the field. This special report is free to access and the precursor to our 500+ page, investment-grade Psychedelic Industry Report, which will be launched at the end of the first financial quarter of the year.

IP & Patents psychedelic industry report

The Critical Role of Intellectual Property & Patents in Psychedelic Drug Development

Not only is psychedelic medicine performing exceptionally well in modern clinical trials, but it is also poised to make a major impact on investors and patients alike. In fact, Canaccord Genuity Group, one of the most prominent investment banks in psychedelic medicine, recently estimated that the psychedelic market will be worth nearly $100 billion. With the recent decriminalization/legalization efforts surrounding psilocybin, the market is in a great position to expand and disrupt the current standard of care. This is an incredible opportunity for advanced and innovative drug developers to create novel psychedelic drugs that can offer massive benefits beyond traditional psychedelic drugs. However, this pathway requires significant capital, time and skill. Patenting is one of the most important steps to bringing a new drug to market. This free report details crucial information about how new psychedelic compounds can be patented and has been compiled by leading experts in this field.

To learn more about the importance of IP & Patents in Psychedelic Drug Development, make sure to read: The Critical Role of Patents in Novel Drug Development

IP & Patents psychedelic industry report

The Microdose Special IP & Patents Report is the Precursor to the Full Psychedelic Industry Report

In addition to this special, free-to-access IP & Patents report, Microdose is pleased to announce the upcoming launch of our signature Microdose Psychedelic Industry Report. This investment-grade market intelligence guide will be launched at the end of quarter one this year in addition to our Psychedelic Industry Online Directory. In an effort to aid stakeholders within the emerging psychedelic industry, the Industry Report includes 10k+ industry data points and covers key insights, market data, sector fundamentals, transactions, clinical trials and important research pertaining to psychedelic medicine. Set to reach a massive audience of investors, clinicians and industry experts, this comprehensive Industry Report is sure to inspire and inform psychedelic medicine enthusiasts about the exciting renaissance that is currently underway.

IP & Patents psychedelic industry report

Shout Out to Our Industry Report Sponsors Who Made This Amazing Undertaking Possible

Microdose is pleased to be collaborating with the leading companies in the psychedelic industry to create this comprehensive report as well as this special IP & Patents Report. Thank you to Zuber Lawler, Psilocybin Alpha, and Calyx Law for contributing content towards this important endeavor. Thank you to our sponsors who are featured in this report: MagicMed Industries, Zuber Lawler, Psygen, Mydecine Innovations Group, Numinus, & Universal Ibogaine.  Through collaborations with thought leaders driving the psychedelic renaissance, we have been able to curate an important and relevant report for this emerging sector. 

Sponsorship opportunities are still available for the full Psychedelic Industry Report; please contact Christina Cassen to discuss: [email protected].

IP & Patents psychedelic industry report

Microdose Psychedelic Insights

Microdose Psychedelic Insights

Your Guide to the Business of Psychedelics. Our mission is to shift the world's perception of psychedelic medicine.